May 7, 2020 / 10:30 PM / 23 days ago

BRIEF-Protagonist - PTG-300 Treatment Shows Provides Clinically Meaningful Dose Related Control Of Hematocrit Values On Individual Patient Basis

May 7 (Reuters) - Protagonist Therapeutics Inc:

* PROTAGONIST THERAPEUTICS ANNOUNCES INITIAL PHASE 2 RESULTS WITH HEPCIDIN MIMETIC PTG-300 IN THE TREATMENT OF POLYCYTHEMIA VERA

* PROTAGONIST - PTG-300 TREATMENT SHOWS PROVIDES CLINICALLY MEANINGFUL DOSE RELATED CONTROL OF HEMATOCRIT VALUES ON INDIVIDUAL PATIENT BASIS

* PROTAGONIST THERAPEUTICS INC - ADMINISTRATION OF PTG-300 WAS WELL TOLERATED AND SAFETY PROFILE WAS GENERALLY SIMILAR WITH RESULTS OF PRIOR STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below